

## *Helicobacter pylori* and Peptic Ulcer Bleeding

*Varocha Mahachai, M.D., F.R.C.P.(C), F.A.C.G.\**  
*Ratha-korn Vilaichone, M.D., Ph.D.\*\**

### ABSTRACT

Peptic ulcer bleeding is a major complication of peptic ulcer disease and carries significant morbidity and mortality. Current evidence suggests that *H. pylori* and NSAIDs increased risk of peptic ulcer bleeding and these two factors seem to act independently. Patients with peptic ulcer bleeding should be tested for *H. pylori* infection, regardless of the use of NSAIDs. Eradication therapy with a proton pump based triple therapy should be given to all *H. pylori*-positive patients. After eradication, acid-suppressant therapy is advised to heal the ulcer. The success of eradication should be confirmed because of the risk of recurrence of peptic ulcer disease and bleeding complication.

**Key words :** *Helicobacter pylori*, peptic ulcer bleeding

[*Thai J Gastroenterol* 2004; 5(1): 24-28]

### INTRODUCTION

Peptic ulcer disease (PUD) is the worldwide health problem and bleeding is the most frequent complication which is occurring in 20% of PUD patients<sup>(1)</sup>. Even though, the improvements of endoscopic hemostatic techniques and acid suppressive drugs, peptic ulcer bleeding remains a life threatening condition that carries 10% mortality rate<sup>(2-4)</sup>. *Helicobacter pylori* (*H. pylori*) is gram negative bacterium and are estimated to colonize about 60% of world population, with higher rate in developing countries. Furthermore, this organ-

ism is a well established cause of PUD and nonvariceal upper gastrointestinal bleeding<sup>(5)</sup>. There is considerable evidence that eradication of the organism markedly alter the natural history, decreases the recurrence and reduces the complication of PUD<sup>(5-9)</sup>. New information on the relationship of *H. pylori* and upper gastrointestinal bleeding is now available.

### The Prevalence of *H. pylori* Infection

*H. pylori* has been detected in more than 90% of patients with duodenal ulcer and approximately 75% of those with gastric ulcers<sup>(10)</sup>. However, The preva-

\* Gastroenterology Unit, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand

\*\* Gastroenterology Unit, Department of Medicine, Thammasat University Hospital, Pathumthani, Thailand

lence of *H. pylori* is lower in patients with complicated PUD. For example, the prevalence of *H. pylori* infection in peptic ulcer bleeding was present in 40-70% in previous report<sup>(11)</sup> and 73% in Thai patients<sup>(6)</sup>. The lower prevalence of *H. pylori* detection in patients with bleeding peptic ulcer could be due to the varying sensitivity and specificity of the *H. pylori* diagnostic tests used in different studies. For example, the rapid urease test on the antral biopsy have been found to have high false negative rate of *H. pylori* infection in bleeding ulcers<sup>(12,13)</sup>. Another explanation, in patients with bleeding peptic ulcer may have factors other than *H. pylori* that are also important in the pathogenesis of the bleeding peptic ulcer. Nonsteroidal anti-inflammatory drugs (NSAIDs) is another important factor which has been found to be the most common cause of PUD in patients who had negative test for *H. pylori*<sup>(14)</sup>. Furthermore, patients factors such as advanced age (>60 years) and concurrent illness could also show to increase bleeding complication and higher mortality rate<sup>(15-18)</sup>.

### Pathophysiology of *H. pylori* and NSAIDs in Development of Bleeding Peptic Ulcer

*H. pylori* infection produces important changes in the physiology of gastric acid production. Levels of the secretory hormone, gastrin, are increased in *H. pylori* infected patients. Release of gastrin from G-cells in the gastric mucosa is controlled by factors that include luminal pH and local somatostatin release by nearby D-cells. Hypergastrinemia associated with *H. pylori* infection is thought to occur secondarily to the release of cytokines (TNF and IL-8) in response to infection and to diminish production of the inhibitory hormone, somatostatin. Infection with *H. pylori* has been associated with decreased levels of somatostatin, diminished somatostatin mRNA production, and fewer somatostatin-producing D-cells<sup>(19,20)</sup>. These imbalances in gastrin and somatostatin production can explain the observed effects of *H. pylori* on acid secretion. Clinically, patients with *H. pylori* infection have increased basal and maximal acid outputs that return to normal levels after the organism is eradicated, which suggests that infection is the cause of increased acid production<sup>(21)</sup>.

### Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs are widely prescribed and have been associated with gastric and duodenal ulcer disease. The

inhibitory effects of NSAIDs on the production of prostaglandin in the stomach have been blamed for their ulcerogenic action. Use of NSAIDs predisposes the patient to the development of gastric and duodenal ulceration, although these drugs are more commonly associated with gastric ulcer. NSAIDs have the potential to induce and to exacerbate PUD, and these drugs have been reported to be an important risk factor for bleeding ulcers. Complications of ulcer disease caused by NSAIDs occur early in the course of NSAID therapy; NSAID-induced complications occur within the first month of therapy<sup>(22)</sup>. When use of NSAIDs is discontinued, NSAID-associated ulcers heal quickly.

### Interaction of *H. pylori* and NSAIDs in Bleeding Peptic Ulcer

Since both *H. pylori* and the use of NSAIDs are the most common cause of peptic ulceration, whether the presence of *H. pylori* infection would affect the risk of ulcers in patients taking NSAIDs is important for both theoretical and practical reasons. The results have been so conflicting that there is no consensus on the management of patients requiring NSAIDs who are infected with *H. pylori*. The controversy is largely due to the variable study design and marked heterogeneity of the study population. However, current evidence suggests that *H. pylori* and NSAIDs increased risk of peptic ulcer bleeding and these two factors seem to act independently<sup>(23,24)</sup>. Our recent study showed that *H. pylori* and NSAIDs increase risk of peptic ulcer bleeding (OR = 3.7, 95%CI = 1.20-11.16 and OR = 3.1, 95%CI = 1.53-6.12 respectively) and they act independently<sup>(6)</sup> confirm the previous observations as summarized in Table 1. Furthermore, recent evidence suggests that *H. pylori* contribute to ulcer bleeding associated with low-dose aspirin. Among *H. pylori*-positive patients with a history of ulcer bleeding who are taking low-dose aspirin, the eradication of *H. pylori*

**Table 1** Result of multivariable model for prediction of UGIB event in Thai population<sup>(6)</sup>

Variables	Odds Ratio (OR)	95% CI	p-value
Current NSAIDs use	3.7	1.20-11.16	<0.05
<i>H. pylori</i> infection	3.1	1.53-6.12	<0.01
NSAIDs & <i>H. pylori</i>	2.9	1.45-5.75	<0.01

has been shown to be comparable to omeprazole in preventing recurrent bleeding<sup>(25)</sup>.

### Diagnostic Tests for *H. pylori* Infection in Peptic Ulcer Bleeding

*H. pylori* diagnostic tests divides into those requiring endoscopy to obtain biopsies of the gastric mucosa and those not requiring endoscopy. Endoscopic tests include gastric mucosal culture, histology and biopsy- rapid urease test (biopsy-RUT). Non-biopsy based tests include serology analysis and urea breath test (UBT). Gastric mucoasal culture remains the gold standard for detecting *H. pylori* and is particularly useful for patients in whom eradication therapy has failed and antimicrobial resistant need to be determined. Although, culture considers the gold standard for diagnosis of *H. pylori* infection, culture is not usually yield on for diagnosis of *H. pylori* infection because the organism is fastidious and the sensitivity of culture often is lower than that of the other tests. Histology is usually related to observer error, sampling error, the density of the organism and the staining methods. However, the experienced pathologist, hematoxylin and eosin stain is adequate for routine clinical purposes. Three (author's standard) or five biopsy specimens (two antral, two corpus and one incisura) as suggested by the Sydney system (revised version) correctly separate infected mucosa from uninfected mucosa. Biopsy-RUT at the antrum is generally considered the initial endoscopic test of choice. The biopsy-RUT is based on the urease producing, urea in the tests is hydrolyzed, releasing ammonia and raising the pH. A color change caused by the pH indicator in the tests denotes a positive result. A false negative biopsy-RUT is common in *H. pylori* associated bleeding peptic ulcers (1) and blood in the stomach is thought to interfere with the biopsy-RUT, the underlying mechanism remains unknown. Our previous study found that exposure of gastric biopsy specimens to their own blood for four hours significantly decreased the sensitivity of the biopsy rapid urease test for *H. pylori* detection<sup>(26)</sup>.

Serologic testing is a useful noninvasive testing strategy for *H. pylori* infection. It appears to be similar to any other bacterial infections (i.e. after approximately 14 days, IgM is present, and by 21 days, IgG is detectable). IgM declines over the next 3 months thus patients with chronic *H. pylori* infection usually have no IgM but always have IgG. The three main formats for the serologic kits are ELISA, immuno-

**Table 2** Comparative of the invasive and non-invasive test of *H. pylori* detection in bleeding peptic ulcers<sup>(1,27)</sup>

Diagnostic tests	Sensitivity (%)	Specificity (%)
Biopsy RUT	47.5	100
Culture	48	91
Histology	82.6	81.8
UBT	93	87.5
Serology	86.4	77.7
HpSA	96.6	33.3

chromatography and Western blotting. The test is not usually to diagnose infection with the bacterium because the result may indicate a prior rather than a current infection. The UBT is a non-invasive and non-endoscopic test that also employs the potent urease test of the bacterium. Patients are required to drink a solution of urea labeled with carbon 13 or 14. Breath samples are collected before and after 30 minutes after the administration of the labeled urea solution. The sensitivity and specificity of this test are good in peptic ulcer bleeding (sensitivity of 93% and specificity of 87.5%)<sup>(27)</sup>. *H. pylori* antigen-based stool assay (HpSA) has proven to be accurate in diagnosing *H. pylori* infection in dyspeptic patients. However, HpSA gave a high number of false positive result in bleeding peptic ulcer, probably because of blood constituents cross reaction in the enzyme immunoassay<sup>(28)</sup>. Comparative of the invasive and non-invasive test of *H. pylori* detection in bleeding peptic ulcers was summarized in Table 2. Since none of the above tests are perfect and the analysis of C13 level requires an expensive mass spectrometer. It is wised to do two diagnostic tests (biopsy RUT and histology) during emergency endoscope in stable patients. If negative, serology is suggested to confirm the absence of *H. pylori*. If positive serology, repeat bioisies or UBT should be done to confirm current *H. pylori* infection. In unstable patient, UBT or endoscopy (biopsy RUT and histology) should be performed later. PPI should be stopped before testing at least 1 week.

### Long Term Outcome for Patients with Bleeding Peptic Ulcer

Before the recognition of the role of *H. pylori* in the pathogenesis of the PUD, approximately 30% of patients with bleeding duodenal ulcer and 20% of patients with bleeding gastric ulcer have repeat bleeding

**Table 3** *H. pylori* eradication reduces the rate of peptic ulcer rebleeding: long term F/U

Studies	Duration of F/U	Rebleeding rate		p-value
		HP eradication	PPI or H2RA only	
Jasperson <i>et al</i> <sup>(31)</sup>	1 year	0%(0/29)	27%(6/22)	<0.01
Macri <i>et al</i> <sup>(32)</sup>	4 years	0%(0/21)	81.8%(9/11)	<0.002
Sung <i>et al</i> <sup>(33)</sup>	6 weeks	0%(0/126)	7.2%(9/124)	<0.05

in 2 to 3 year after the first episode<sup>(29,30)</sup>. Numbers of studies demonstrate that eradication of *H. pylori* reduces the rebleeding significantly than those with persistent *H. pylori* infection as summarized in Table 3.

In summary, all patients with peptic ulcer bleeding should be tested for *H. pylori* infection, regardless of the use of NSAIDs. Because invasive tests are less sensitive in peptic ulcer bleeding patients, negative tests in patients with no other risk factors should be confirmed by UBT. Eradication therapy with a proton pump inhibitor or ranitidine bismuth citrate-based triple therapy should be given to all *H. pylori*-positive patients. After eradication therapy, acid-suppressant therapy is advised to heal the ulcer. The success of eradication should always be confirmed because of the risk of recurrence of peptic ulcer disease and bleeding in *H. pylori*-infected patients.

#### REFERENCES

- Mahachai V, Vilaichone RK, Kullavanijaya P. Diagnosis method of *Helicobacter pylori* infection in bleeding peptic ulcer. *J Med Assoc Thai* 2002; 85 (Suppl 1): S103-8.
- Rockall TA, Logan RF, Devlin HB, *et al*. Incidence of and mortality from acute upper gastrointestinal hemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Hemorrhage. *Br Med J* 1995; 311(6999): 222-6.
- Laine L. Multipolar electrocoagulation in the treatment of active upper gastrointestinal tract hemorrhage. A prospective controlled trial. *N Engl J Med* 1987; 316: 1613-7.
- Panes J, Viver J, Forne M, *et al*. Controlled trial of endoscopic sclerosis in bleeding peptic ulcers. *Lancet* 1987; 2(8571): 1292-4.
- Graham DY, Lew GM, Klein PD, *et al*. Effect of treatment of *Helicobacter pylori* infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. *Ann Intern Med* 1992; 116: 705-8.
- Kullavanijaya P, Vilaichone RK, Thong-Ngam D, *et al*. *Helicobacter pylori* infection as the predictor of upper gastrointestinal bleeding in NSAIDs users. *Gut* 2002; 11 (Suppl): A 97.
- NIH Consensus Conference. *Helicobacter pylori* in peptic ulcer disease. NIH Consensus Development Panel on *Helicobacter pylori* in Peptic Ulcer Disease. *JAMA* 1994; 272: 65-9.
- Hentschel E, Brandstatter G, Dragosics B, *et al*. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of *Helicobacter pylori* and the recurrence of duodenal ulcer. *N Engl J Med* 1993; 328: 308-12.
- Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of *Helicobacter pylori*. *Lancet* 1990; 335(8700): 1233-5.
- Marshall BJ. *Helicobacter pylori*. *Am J Gastroenterol* 1994; 89(Suppl 8): S116-28.
- Callicutt CS, Behrman SW, Callicutt CS, Behrman SW. *J Gastrointest Surg* 2001; 5: 614-9.
- Lai KC, Hui HM, Lam SK. Bleeding ulcer have high false negative rates for antral *Helicobacter pylori* when tested with urease test (abstract). *Gastroenterology* 1996; 110: 167A.
- Peitz U, Leodolter A, Wex T, *et al*. Diagnostics of *Helicobacter pylori* Infection in Patients with Peptic Ulcer Bleeding. *Z Gastroenterol* 2004; 42: 141-4.
- McCull KE, el-Nujumi AM, Chittajallu RS, *et al*. A study of the pathogenesis of *Helicobacter pylori* negative chronic duodenal ulceration. *Gut* 1993; 34: 762-8.
- Branicki FJ, Boey J, Fok PJ, *et al*. Bleeding duodenal ulcer. A prospective evaluation of risk factors for rebleeding and death. *Ann Surg* 1990; 211: 411-8.
- Mueller X, Rothenbuehler JM, Amery A, *et al*. Factors predisposing to further hemorrhage and mortality after peptic ulcer bleeding. *J Am Coll Surg* 1994; 179: 457-61.
- Branicki FJ, Coleman SY, Fok PJ, *et al*. Bleeding peptic ulcer: a prospective evaluation of risk factors for rebleeding and mortality. *World J Surg* 1990; 14: 262-9; discussion 269-70.
- Larson G, Schmidt T, Gott J, *et al*. Upper gastrointestinal bleeding: predictors of outcome. *Surgery* 1986; 100: 765-73.
- Odum L, Petersen HD, Andersen IB, *et al*. Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa. *Gut* 1994; 35: 615-8.
- Moss SF, Legon S, Bishop AE, *et al*. Effect of *Helicobacter pylori* on gastric somatostatin in duodenal ulcer disease.

- Lancet 1992; 17; 340(8825): 930-2.
21. el-Omar EM, Penman ID, Ardill JE, *et al.* *Helicobacter pylori* infection and abnormalities of acid secretion in patients with duodenal ulcer disease. *Gastroenterology* 1995; 109: 681-91.
  22. Laine L, Peterson WL. Bleeding peptic ulcer. *N Engl J Med* 1994; 331: 717-27.
  23. van Leerdam ME, Tytgat GN. *Helicobacter pylori* infection in peptic ulcer haemorrhage. *Aliment Pharmacol Ther* 2002; 16 (Suppl 1): 66-78.
  24. Stack WA, Atherton JC, Hawkey GM, *et al.* Interactions between *Helicobacter pylori* and other risk factors for peptic ulcer bleeding. *Aliment Pharmacol Ther* 2002; 16: 497-506.
  25. Chan FK, Chung SC, Suen BY, *et al.* Preventing recurrent upper gastrointestinal bleeding in patients with *Helicobacter pylori* infection who are taking low-dose aspirin or naproxen. *N Engl J Med* 2001; 344: 967-73.
  26. Tangmankongworakoon N, Vilaichone RK, Kullavanijaya P, *et al.* The effect of blood on rapid urease test for *Helicobacter pylori* detection: an in vitro study. *J Med Assoc Thai* 2002; 85 (Suppl 1): S70-3.
  27. Castillo-Rojas G, Ballesteros MA, Ponce de Leon S, *et al.* Bleeding peptic ulcers and presence of *Helicobacter pylori* by various tests: a case-control study. *Eur J Gastroenterol Hepatol* 2002; 14: 1113-8.
  28. van Leerdam ME, van der Ende A, ten Kate FJ, *et al.* Lack of accuracy of the noninvasive *Helicobacter pylori* stool antigen test in patients with gastroduodenal ulcer bleeding. *Am J Gastroenterol* 2003; 98: 798-801.
  29. Rorbaek-Madsen M, Fischer L, Thomsen H, *et al.* Late outcome of bleeding gastric ulcer. Five to eight years' follow-up. *Scand J Gastroenterol* 1994; 29: 983-7.
  30. Jensen DM, Cheng S, Kovacs TO, *et al.* A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. *N Engl J Med* 1994; 330: 382-6.
  31. Jaspersen D, Koerner T, Schorr W, *et al.* *Helicobacter pylori* eradication reduces the rate of rebleeding in ulcer hemorrhage. *Gastrointest Endosc* 1995; 41: 5-7.
  32. Macri G, Milani S, Surrenti E, *et al.* Eradication of *Helicobacter pylori* reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. *Am J Gastroenterol* 1998; 93: 925-7.
  33. Sung JJ, Leung WK, Suen R, *et al.* One-week antibiotics versus maintenance acid suppression therapy for *Helicobacter pylori*-associated peptic ulcer bleeding. *Dig Dis Sci* 1997; 42: 2524-8.